Optimizing Treatment Selection After Progression in HER2+ Metastatic Breast Cancer

home / around-the-practice / optimizing-treatment-selection-after-progression-in-her2-metastatic-breast-cancer

Panelists discuss how evolving treatment options, including T-DXd and tucatinib-based regimens, are reshaping the management of HER2+ metastatic breast cancer in later-line settings, emphasizing the importance of personalized therapy and proactive toxicity management.

Overview of Clinical Data and Treatment Selection in Later-Line HER2+ Metastatic Breast Cancer

EP. 1: Overview of Clinical Data and Treatment Selection in Later-Line HER2+ Metastatic Breast Cancer

VK Gadi, MD, PhD;Ruta Rao, MD;Jane L. Meisel, MD
December 23rd 2024

Panelists discuss how clinical data and treatment selection in later-line HER2+ metastatic breast cancer are informed by the latest therapeutic advancements, including targeted therapies like trastuzumab deruxtecan (T-DXd) and tucatinib, to optimize patient outcomes and manage progression.

Managing T-DXd-Related Toxicity and Intolerance in Later-Line HER2+ Breast Cancer

EP. 2: Managing T-DXd-Related Toxicity and Intolerance in Later-Line HER2+ Breast Cancer

VK Gadi, MD, PhD;Ruta Rao, MD;Jane L. Meisel, MD
January 2nd 2025

Panelists discuss how managing trastuzumab deruxtecan (T-DXd)–related toxicity and intolerance in later-line HER2+ breast cancer requires close monitoring, early detection of adverse effects like interstitial lung disease, and strategic adjustments to treatment regimens for improved patient safety and outcomes.

Third-Line Approach: 54-Year-Old Patient Treated With Tucatinib-Based Regimen

EP. 3: Third-Line Approach: 54-Year-Old Patient Treated With Tucatinib-Based Regimen

VK Gadi, MD, PhD;Ruta Rao, MD;Jane L. Meisel, MD
January 6th 2025

Panelists discuss how a third-line approach for a 54-year-old patient treated with a tucatinib-based regimen involves careful consideration of prior treatment responses, comorbidities, and the potential benefits of combining tucatinib with capecitabine and trastuzumab to improve outcomes in HER2+ metastatic breast cancer.

Evolving Landscapes: Personalized Approaches in Later-Line HER2+ Treatment

EP. 4: Evolving Landscapes: Personalized Approaches in Later-Line HER2+ Treatment

VK Gadi, MD, PhD;Ruta Rao, MD;Jane L. Meisel, MD
January 13th 2025

Panelists discuss how a third-line approach for a 54-year-old patient treated with a tucatinib-based regimen involves careful consideration of prior treatment responses, comorbidities, and the potential benefits of combining tucatinib with capecitabine and trastuzumab to improve outcomes in HER2+ metastatic breast cancer.